Canopus BioPharma Incorporated
CBIA · OTC
8/31/2022 | 8/31/2021 | 6/30/2014 | 6/30/2013 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.00 | 0.00 | 0.74 | 0.00 |
| FCF Yield | -0.06% | -0.04% | 18.94% | -85.98% |
| EV / EBITDA | -14.35 | -2,232.14 | -110.54 | -43.22 |
| Quality | ||||
| ROIC | 25,400.66% | 27.83% | -39.00% | -8.32% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.01 | 1.00 | -2.27 | 1.03 |
| Growth | ||||
| Revenue 3-Year CAGR | – | – | -100.00% | -100.00% |
| Free Cash Flow Growth | -252.14% | 0.00% | 454.37% | 0.00% |
| Safety | ||||
| Net Debt / EBITDA | -0.01 | 0.64 | -16.78 | -37.39 |
| Interest Coverage | -5,272.83 | 0.00 | -1.32 | -0.30 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | 0.00 |